Tectonic Therapeutic Inc(TECX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.56 | Insider Own | 48% | Shs Outstand | 19.2M | Perf Week | -5.86% |
| Market Cap | 0.40B | Forward P/E | - | EPS next Y | -2.84% | Insider Trans | -0.02% | Shs Float | 10.2M | Perf Month | -11.91% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -1.32 | Inst Own | 61.44% | Short Float | 21.87% | Perf Quarter | -27.88% |
| Income | -0.09B | P/S | - | EPS this Y | -27.62% | Inst Trans | 1.41% | Short Ratio | 10.14 | Perf Half Y | -24.05% |
| Sales | 0.00B | P/B | 1.77 | EPS next 5Y | -13.91% | ROA | -32.23% | Short Interest | 2.22M | Perf YTD | -1.44% |
| Book/sh | 11.64 | P/C | 1.77 | EPS past 3/5Y | 48.16% 36.65% | ROE | -33.8% | 52W High | -47.99% ($39.53) | Perf Year | 14.99% |
| Cash/sh | 11.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.85% | 52W Low | 32.47% ($15.52) | Perf 3Y | 12.72% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -13.09% | Gross Margin | - | Volatility(W/M) | 6.12% 5.38% | Perf 5Y | -69.18% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 22.29 | EPS Q/Q | -9.84% | Profit Margin | - | RSI (14) | 34.36 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 22.29 | Sales Q/Q | - | SMA20 | -5.02% ($21.65) | Beta | 1.28 | Target Price | $71 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | -22.89% ($26.66) | Rel Volume | 0.98 | Prev Close | $20.34 |
| Employees | 60 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 12.51% - | SMA200 | -26.78% ($28.08) | Avg Volume(3M) | 0.22M | Price | $20.56 |
| IPO | 2018/6/21 | Option/Short | Yes/Yes | Trades | 2762 | Volume | 215,900 | Change | 1.08% |
🧬 Tectonic Therapeutic (TECX) is a clinical-stage biotech company developing protein and antibody therapeutics that target a class of proteins known as G protein-coupled receptors (GPCRs). Leveraging its proprietary GEODe platform, the company aims to overcome long-standing challenges in GPCR drug discovery and is advancing its pipeline around its lead candidate, TX45, in pulmonary hypertension. It is headquartered in the United States.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
TECX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -27.6% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -69.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #241 of 594 in the industry
Based on market cap of $402M.
ALT#238 Altimmune Inc $408M PER - 
NAUT#238 Nautilus Biotechnology Inc $408M PER - 
RZLT#240 Rezolute Inc $408M PER - TECX#241 Tectonic Therapeutic Inc $402M PER - 
TRXB#242 Trex Bio Inc $396M PER - 
FAQ
What kind of company is TECX?
TECX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TECX?
The market cap of TECX is approximately $402M, ranking 3,341 within its sector.
What is the 52-week high and low for TECX?
TECX has recorded a 52-week high of $39.53 and a low of $15.52.
